Want to see JP:4571 full AI Analyst Report?
4571 Stock Chart & Stats
¥134.00
-¥1.00(-0.68%)
At close: 4:00 PM EST
¥134.00
-¥1.00(-0.68%)
Day’s Range― - ―
52-Week Range¥95.00 - ¥254.00
Previous CloseN/A
Volume236.30K
Average Volume (3M)2.35M
Market Cap
¥8.02B
Enterprise Value¥4.90B
Total Cash (Recent Filing)¥4.91B
Total Debt (Recent Filing)¥1.60B
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.91
Shares Outstanding83,536,760
10 Day Avg. Volume484,410
30 Day Avg. Volume2,345,523
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)3.10
Price to Sales (P/S)63.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Technology And Partner ModelNanoCarrier’s core asset is a proprietary micelle-based drug‑delivery platform and an explicit partnering/licensing business model. This structural model leverages external R&D and commercialization capabilities, enabling recurring milestone and royalty revenue streams while lowering solo commercialization burden and preserving scientific moat over the medium term.
Strong Revenue ReboundA sizable, sustained revenue rebound indicates improving partner uptake or milestone recognition and validates the commercial relevance of the technology. Over 2–6 months this trend supports stronger partner negotiation leverage, higher probability of future milestones/royalties, and a clearer path to scaling revenue if the company sustains commercialization traction.
Very High Gross MarginsConsistently elevated gross margins reflect strong economics on sales and licensing of the nanocarrier platform. High product-level margins are durable advantages: they create room to absorb SG&A and R&D as revenues scale, increase the value of future royalty streams, and improve incremental profitability once fixed costs normalize or partner-funded programs expand.
Bears Say
Persistent Operating And Net LossesThe company has sustained operating and net losses over multiple years, which erode retained earnings and constrain reinvestment. Over the medium term this persistent unprofitability raises reliance on external financing, increases dilution risk, and limits the firm’s ability to self-fund late-stage development or commercial launches without partner funding.
Consistently Negative Operating Cash FlowNegative operating cash flow means the core business is a net cash consumer rather than generator. Structurally, this forces dependence on financing or partner payments to sustain operations and clinical programs, heightening refinancing and execution risk and reducing flexibility to invest in pipeline advancement or respond to adverse events.
Rising Debt And Negative Returns On EquityMeaningful debt growth combined with persistently negative ROE signals financial strain and value destruction. Higher leverage raises fixed obligations and restricts strategic optionality, while negative returns reduce investor and partner confidence. Over months this can constrain deal terms, increase financing cost, and pressure the balance sheet if revenue volatility continues.
NanoCarrier Co., Ltd. News
4571 FAQ
What was NanoCarrier Co., Ltd.’s price range in the past 12 months?
NanoCarrier Co., Ltd. lowest stock price was ¥95.00 and its highest was ¥254.00 in the past 12 months.
What is NanoCarrier Co., Ltd.’s market cap?
NanoCarrier Co., Ltd.’s market cap is ¥8.02B.
When is NanoCarrier Co., Ltd.’s upcoming earnings report date?
NanoCarrier Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 13 days.
How were NanoCarrier Co., Ltd.’s earnings last quarter?
NanoCarrier Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥3.84 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.84.
Is NanoCarrier Co., Ltd. overvalued?
According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued.
Does NanoCarrier Co., Ltd. pay dividends?
NanoCarrier Co., Ltd. does not currently pay dividends.
What is NanoCarrier Co., Ltd.’s EPS estimate?
NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoCarrier Co., Ltd. have?
NanoCarrier Co., Ltd. has 83,536,760 shares outstanding.
What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?
NanoCarrier Co., Ltd. reported an EPS of -¥3.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4571
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoCarrier Co., Ltd.
NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.
Technical Analysis
AnGes
―
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
STELLA PHARMA CORPORATION
―